8 results about "Oral hypoglycemic" patented technology

A Smad5 mutant and uses thereof in the prevention and treatment of diabetes. The amino acid sequence of the Smad5 mutant is as shown in SEQ NO ID:1. The invention further relates to a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid, and a transformant. The uses also comprise uses of the nucleic acid, the recombinant expression vector containing the nucleic acid, and the transformant in the preparation of a medicament for preventing and / or treating diabetes. The Smad5 mutant can improve symptoms of type 1 and type 2 diabetes in vivo, and, compared with conventional oral hypoglycemic drugs, has no toxic or side effects and does not cause damage to the liver or kidneys of patients. In addition, the invention relates to a reagent for regulating acid-base balance, comprising alkaline drinking water containing baking soda; the reagent can lower blood glucose, alleviate diabetic symptoms, and is more economical and convenient for patients to use.

The application discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of a transgenic lettuce and an oral hypoglycemic drug, relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO:1.The recombinant protein, i.e., a human transferrin-proinsulin fusion protein, can utilize the natural combination of the human transferrin-transferrin receptor to mediate the endocytosis transport of proinsulin after being orally taken, pass through the intestinal tract to enter the blood system, and reduce blood sugar.According to animal experiments, the effect of the recombinant protein is close to that of natural insulin, and the recombinant protein realizes oral delivery of insulin.

The invention provides a novel oral blood sugar reducing polypeptide. The polypeptide is an improved derivative based on Exendin-4. According to the present invention, the Exendin-4 is analyzed so as to obtain the core sequence of 28 amino acids, wherein the core sequence is HGEGTFTSDLSKQMEEEAVRLFIEWLKN; in order to improve the stability and bioavailability, four key sites are subjected to amino acid substitution (K12H, R20H, F22A and K27H), AF and FK are respectively added at the N end and the C end, and finally a complete sequence with 32 amino acids is formed. The structural modifications significantly improve the oral absorption efficiency of the polypeptide. Compared with an Exendin-4 prototype, the antihyperglycemic polypeptide Ex32 disclosed by the invention has the advantages that the enzymolysis resistance is obviously improved, and the obtained Ex32-containing polypeptide has good physical and chemical stability and bioavailability and can be directly used for preparing various dosage forms, for example, the Ex32-containing polypeptide can be used for treating type II diabetes mellitus.

The application discloses a Smad5 mutant and application thereof in preventing and treating diabetes.The amino acid sequence of the Smad5 mutant is shown as SEQ NO ID:1.The application further discloses a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid and a transformant.The application also includes the application of the nucleic acid, the recombinant expression vector containing the nucleic acid and the transformant in preparing a medicine for preventing and / or treating diabetes.The Smad5 mutant can improve the symptoms of type 1 diabetes and type 2 diabetes in vivo, and has no toxic side effects compared with conventional oral hypoglycemic drugs, and has no damage to the liver and kidney of patients.In addition, an agent for regulating acid-base balance is disclosed, which comprises baking soda alkaline drinking water; the agent can reduce blood sugar and relieve the symptoms of diabetes, and is more economical and convenient to operate for patients.

The invention belongs to the field of medicine and provides a medicine for treating or assisting in treating diabetes. The medicine is prepared by containing the following components in parts by weight: 15-25 parts by weight of ginseng; 52-68 parts by weight of prepared rehmannia; 54-65 parts by weight of figwort; 25-35 parts by weight of cornus officinalis; 51-67 parts by weight of dodder seed; 36-45 parts by weight of atractylodes; 26-34 parts by weight of millettia reticulata; 50-70 parts by weight of agrimony; 21-27 parts by weight of rhubarb; 16-25 parts by weight of cinnamon bark; 35-45 parts by weight of coptis root; 11-21 parts by weight of leech; 53-68 parts by weight of astragalus; 52-68 parts by weight of mulberry bark; gypsum: 210-275 parts by weight; 25-36 parts by weight of anemarrhena; and 24-35 parts by weight of salvia miltiorrhiza. This drug can be used alone or in combination with insulin injection / oral hypoglycemic Western medicine, and has a significant therapeutic effect on diabetes.

The invention discloses a polyhydroxy onium salt derivative as well as a preparation method and application thereof, and the onium salt derivative with a brand new structure is designed on the basis of the structure of a natural product through principles of skeleton transition, bioisostere and the like. Compared with a natural product and a reported analogue, the onium salt compound has stronger alpha-glucosidase inhibitory activity and activity of reducing postprandial blood sugar in a mouse body, can be used as an onium salt type alpha-glucosidase inhibitor oral hypoglycemic drug, and is mainly prepared from D-arabinose as a raw material, the onium salt derivative molecule with alpha-glucosidase inhibitory activity is obtained through multi-step reaction, and the molecule has remarkable in-vivo blood sugar reducing activity.

The application discloses a dual-unit fluorescent sensor array for detecting oral anti-diabetic drugs and application thereof, and relates to a supramolecular fluorescent sensor array which comprises a PAL@Q[8] sensing unit and a bpep-Am@Q[8] sensing unit, wherein the PAL@Q[8] sensing unit is composed of palmatine and Q[8], and the bpep-Am@Q[8] sensing unit is composed of a derivative of 1,4-bis[2-(4-pyridyl)vinyl]benzene and Q[8]. The dual-unit fluorescent sensor array can be used for qualitative detection and quantitative detection of metformin, phenformin, buformin hydrochloride, rosiglitazone and sitagliptin in serum or urine, and the method provides a simple and reliable analysis tool for rapid screening of oral hypoglycemic drugs, clinical blood drug concentration monitoring and identification of hypoglycemia causes, so as to realize on-site rapid visual analysis of oral hypoglycemic drugs.

The invention discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of transgenic lettuce and an oral hypoglycemic drug, and relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is as shown in SEQ ID NO: 1. The recombinant protein provided by the invention, namely the human transferrin-proinsulin fusion protein, can mediate endocytosis transport of proinsulin by utilizing the natural binding action of a human transferrin-transferrin receptor after being orally taken, and penetrates through the intestinal tract to enter a blood system, so that the blood sugar is reduced. Animal experiments show that the effect of the recombinant protein provided by the invention is close to that of natural insulin, and the recombinant protein provided by the invention realizes oral delivery of insulin.